SAVA - Cassava Sciences And Alzheimer's Disease: Opaque Clarity

2024-02-10 04:24:58 ET

Summary

• Cassava Sciences' handling of data for simufilam is confusing and raises doubts about FDA approval for Alzheimer's disease.
• Simufilam does not help those with moderate Alzheimer's disease, but may have potential for those with mild cognitive impairment.
• The true impact of simufilam on mild Alzheimer's disease patients is unknown, making it difficult to assess the drug's effectiveness for this group.

I have often been critical of Cassava Sciences (SAVA) handling of data ( articles ) and will be once again. The company's presentation of its two year results for simufilam is confounding, but not impenetrable. This is probably the last material news that will boost Cassava Sciences' stock value prior to (or leading up to) its phase 3 clinical trial results....

For further details see: